Outcomes of patients with relapsed low-grade lymphoma retreated with rituximab are similar to rituximab naïve patients

Abi VijenthiraPostgraduate Medical Education, University of Toronto, Toronto, Canada;

Manjula MagantiDepartment of Biostatistics, Princess Margaret Cancer Centre, Toronto, Canada;

Vishal KukretiDivision of Medical Oncology and Hematology, Department of Medicine, University of Toronto, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada

John KuruvillaDivision of Medical Oncology and Hematology, Department of Medicine, University of Toronto, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada

Rodger TiedemannDivision of Medical Oncology and Hematology, Department of Medicine, University of Toronto, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada

Christine ChenDivision of Medical Oncology and Hematology, Department of Medicine, University of Toronto, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada

Michael CrumpDivision of Medical Oncology and Hematology, Department of Medicine, University of Toronto, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada

Anca PricaDivision of Medical Oncology and Hematology, Department of Medicine, University of Toronto, Princess Margaret Cancer Centre, University Health Network, Toronto, CanadaCorrespondence[email protected]

show all

References

Dreyling MH, Forstpointner R, Ludwig W, et al. Combined immuno-chemotherapy (R-FCM) results in superior remission rates and overall survival in recurrent follicular and mantle cell lymphoma – follow-up of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). JCO. 2005;23:6528–6528.
Web of Science ®Google Scholar
Forstpointner R, Dreyling M, Repp R, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2004;104:3064–3071.
PubMed Web of Science ®Google Scholar
van Oers MHJ, Van Glabbeke M, Giurgea L, et al. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. JCO. 2010;28:2853–2858.
PubMed Web of Science ®Google Scholar
Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–586.
PubMed Web of Science ®Google Scholar
Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–383.
PubMedGoogle Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Outcomes of patients with relapsed low-grade lymphoma retreated with rituximab are similar to rituximab naïve patients

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Outcomes of patients with relapsed low-grade lymphoma retreated with rituximab are similar to rituximab naïve patients

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date